Showing 8311-8320 of 9964 results for "".
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology&mda
- Michael Mazen Jafar is New Chief Marketing Officer at Evolushttps://practicaldermatology.com/news/michael-mazen-jafar-is-new-chief-marketing-officer-at-elovus/2457722/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- New Data from DermTech Presented at International Investigational Dermatology Meetinghttps://practicaldermatology.com/news/new-data-from-dermtech-presented-at-international-investigational-dermatology-meeting/2457724/DermTech, Inc., has announced the publication of two clinical study abstracts at the 2018 International Investigational Dermatology meeting
- Older Melanoma Patients May Have Better Response to Immune Checkpoint Blockade Therapyhttps://practicaldermatology.com/news/older-melanoma-patients-may-have-better-response-to-immune-checkpoint-blockade-therapy/2457728/Patient age correlates with response to immunotherapy in melanoma, and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study resul
- PellePharm Presents New Data in BCChttps://practicaldermatology.com/news/pellepharm-presents-new-data-in-bcc/2457731/PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, presented new data from its clinical and scientific research programs at the International Investigative Dermatology (IID) Meeting in Orlando, FL. The data, presented i
- New CFO at Evolus, Inc.https://practicaldermatology.com/news/new-cfo-at-evolus-inc/2457744/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- Psoriatic Arthritis Awareness Project Launcheshttps://practicaldermatology.com/news/psoriatic-arthritis-awareness-project-launches/2457751/In recognition of Psoriatic Arthritis Action Month, the National Psoriasis Foundation (NPF), in collaboration with Novartis Pharmaceuticals Corporation, has premiered the Psoriatic Arthritis (PsA) Awareness Project. The PsA Awareness Project is a set of patient films that highlight the impo
- New PSA From American Academy of Dermatology Highlights Dangers of Tanninghttps://practicaldermatology.com/news/new-psa-from-american-academy-of-dermatology-highlights-dangers-of-tanning/2457753/As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside— and some may want to get a tan. But a new public service advertisement from the American Academy of Dermatology encourages those who are thinking of tanning to
- Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meetinghttps://practicaldermatology.com/news/glenmark-pharmaceuticals-presents-new-data-on-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-iid-meeting/2457760/Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID)
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat